

## Primary Care HEDIS Measures

		HEDIS 2014?	CMS Star?	Specification File
<b>Key</b>	<b>Population Health Measures</b>			
1 BSC	Breast Cancer Screening	Y	Y	Breast_Cancer_Screening.pdf
2 CCS	Cervical Cancer Screening	Y		Cervical_Cancer_Screen.pdf
3 CHL	Chlamydia Screening	Y		Chlamydia_Screen.pdf
	Age 16 - 20			
	Age 21 - 24			
	Overall			
4 COL	Colorectal Cancer Screening	Y	Y	Colorectal_Cancer_Screen.pdf
5 CIS	Childhood Immunization Status	Y		
	Chicken Pox Vaccine			Chicken_Pox_Vaccine.pdf
	Diphtheria Tetanus Pertussis Vaccine			Diphtheria-Tetanus-Pertussis_Vaccine.pdf
	Hepatitis B Vaccine			Hepatitis_B_Vaccine.pdf
	H Influenza Type B Vaccine			H_Influenza_TypeB_Vaccine.pdf
	Measles Mumps Rubella Vaccine			Measles-Mumps-Rubella_Vaccine.pdf
	Pneumococcal Conjugate Vaccine			Pneumococcal_Conjugate_Vaccine.pdf
	Polio Vaccine			Polio_Vaccine.pdf
	<b>Well-Child Visits</b>			
8 W15	Well-Child Visits in the First 15 Months of Life	Y		Well-Child Visits in the First 15 Months of Life.pdf
9 W34	Well-Child Visits in the 3 - 6 Years of Life	Y		Well-Child Visits in the Third Fourth Fifth.pdf
10 AWC	Adolescent Well Care Visits	Y		Adolescent Well-Care Visits.pdf
	<b>Managing Chronic Conditions</b>			
	<i>Comprehensive Diabetes Care</i>			
11 CDC-H1C	Hemoglobin A1c (HbA1c) Testing	Y		09_CDC_Spec.pdf
	HbA1C Good Control (<7%)	Y	Y	Diabetes_HbA1c_Test.pdf
	HbA1C Adequate Control (<8%)	Y	Y	Diabetes-HbA1c_LessThan_8percent.pdf
	HbA1C Poor Control (>9%)	Y	Y	
12 CDC-EE	Eye Exam (Retinal)	Y	Y	Diabetes-Eye_Exam.pdf

13	CDC-LDL	Cholesterol Management for Patient with Diabetes			
		LDL-C Testing	Y	Y	Diabetes-Lipid_Test.pdf
		LDL-C Control (<100 mg/dl)	Y	Y	Diabetes-LDL-C_LessThan_100mg.pdf
14	CDC-MA	Medical Attention for Nephropathy	Y	Y	Diabetes-Microalbumin_Test.pdf
15	CDC-BP	Blood Pressure Control	Y		
		<140/90 mmHg			
		<140/80 mmHg			
		<i>Additional Chronic Care Measure</i>			
16	AMR	Asthma Medication Ratio	Y		Asthma_Medication_Management.pdf
		Age 5 - 11			
		Age 12 - 18			
		Age 19 - 50			
		Age 51 - 64			
		Overall			
17	CMC	Cholesterol Management for Patient with Cardiovascular Conditions	Y	Y	
		LDL-C Testing	Y	Y	CAD_Event-Cholesterol_Test.pdf
		LDL-C Control (<100 mg/dl)	Y	Y	CAD-LDL-C_Less_than_100mg.pdf
18	MPM	Annual Monitoring for Patients on Persistent Medication	Y	Y	
		ACE Inhibitors or ARBs			AnnualMonitoring-ACE_ARB_Drugs.pdf
		Digoxin			AnnualMonitoring-Digoxin.pdf
		Diuretics			AnnualMonitoring-Diuretics.pdf
		Anticonvulsants Carbamazepine			AnnualMonitoring-Anticonvulsant-Carbamazepine.pdf
		Anticonvulsants Phenobarbital			AnnualMonitoring-Anticonvulsant-Phenobarbital.pdf
		Anticonvulsants Phenytoin			AnnualMonitoring-Anticonvulsant-Phenytoin.pdf
		Anticonvulsants Valproic Acid			AnnualMonitoring-Anticonvulsant-Valproic_Acid.pdf
		Overall			
		<b>Other Measures</b>			
19	CWP	Appropriate Testing for Children with Pharyngitis	Y		Pharyngitis_Treatment-Children.pdf
20	URI	Appropriate Treatment for Children with Upper Respiratory Infection	Y		URI_Treatment_Without_Antibiotics-Children.pdf
21	AAB	Avoidance of Antibiotics Treatment in Adults with Acute Bronchitis	Y		Acute_Bronchitis_Tx_Without_Antibiotics.pdf
22	LBP	Use of Imaging Studies for Low Back Pain	Y		Low_Back_Pain_Imaging_Studies.pdf

Age group	USA 100% (percent of the population)			
Population	308 745 538	Age	% population	
0-4	20 201 362 (6.5%)	0-4	6.5	65
9-May	20 348 657 (6.6%)	5-9	6.6	131
14-Oct	20 677 194 (6.7%)	10-14	6.7	198
15-19	22 040 343 (7.1%)	15-19	7.1	269
20-24	21 585 999 (7.0%)	20-24	7	339
25-29	21 101 849 (6.8%)	25-29	6.8	407
30-34	19 962 099 (6.5%)	30-34	6.5	472
35-39	20 179 642 (6.5%)	35-39	6.5	537
40-44	20 890 964 (6.8%)	40-44	6.8	605
45-49	22 708 591 (7.4%)	45-49	7.4	679
50-54	22 298 125 (7.2%)	50-54	7.2	751
55-59	19 664 805 (6.4%)	55-59	6.4	815
60-64	16 817 924 (5.4%)	60-64	5.4	869
65-69	12 435 263 (4.0%)	65-69	4	909
70-74	9 278 166 (3.0%)	70-74	3	939
75-79	7 317 795 (2.4%)	75-79	2.4	963
80-84	5 743 327 (1.9%)	80-84	1.9	982
85+	5 493 433 (1.8%)	85+	1.8	1000

0.2588996764



